NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.

Abstract

Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co… (More)
DOI: 10.1016/j.jcv.2016.06.012

Topics

Cite this paper

@article{Sevastianova2016NS5ARL, title={NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.}, author={Ksenia Sevastianova and J. Michael Dean and Ciaran L Bannan and Miriam Coghlan and Gillian G Farrell and Catherine M. Murray and Cillian F. De Gascun and Colm J. Bergin}, journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, year={2016}, volume={82}, pages={66-69} }